First AD

Second AD

First-Line Treatment Options in HR+/HER2- and Challenges with Treatment Resistance 

What is your approach to selecting a first-line treatment options for HR+/HER2- breast cancer? Please provide a high-level overview of SOC treatment options in the first-line?

What are primary considerations in selecting a first-line treatment?

What proportion of patients with HR+/HER2- breast cancer experience resistance to first-line endocrine therapy (ET) + CDK4/6 inhibitor?

What does disease progression after first-line treatment look like?

What is the typical timing of disease progression after first-line treatment?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

Targeting the PI3K/AKT/PTEN Pathway in HR+/HER2- Locally Advanced and Metastatic Breast Cancer

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PI3 alterations, AKT alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions. 